namodenoson (CF102) / Can-Fite, China Medical System, Chong Kun Dang, Ewopharma - LARVOL DELTA

Durable Disease Stabilization with Namodenoson in Advanced Pancreatic Adenocarcinoma: Results from a Phase 2a Study (ESMO 2026) - No abstract available

Metastases • P2a data • Oncology • Pancreatic Adenocarcinoma

Advances in Clinical Programs: Pancreatic Cancer (GlobeNewswire) - "Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and demonstrated durable overall survival outcomes. The open-label Phase IIa study enrolled 20 patients with advanced pancreatic ductal adenocarcinoma who had progressed following standard therapies. Fourteen patients received Namodenoson as third-line treatment, five as second-line treatment, and one as fourth-line treatment. Namodenoson was well tolerated. Overall survival findings identify a subset of heavily pretreated pancreatic cancer patients achieving prolonged survival despite receiving Namodenoson as third-line therapy....An abstract highlighting the positive results has been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Congress 2026."

P2a data • Pancreatic Ductal Adenocarcinoma

Can-Fite BioPharma…announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma (HCC) appears longer than originally anticipated based on the assumptions underlying the study design. (Can-Fite Biopharma Press Release) - "The observed survival reflects the pooled, blinded study population and includes patients receiving both Namodenoson and placebo. Accordingly, no conclusions regarding treatment efficacy or differences between the study arms can be drawn from these data at this stage....In view of the longer-than-anticipated survival observed in the study population, Can-Fite is evaluating an earlier timing for the study’s planned interim analysis. The interim analysis will enable an independent assessment of overall survival between the Namodenoson and placebo treatment groups in accordance with the study’s statistical analysis plan and applicable regulatory requirements."

P3 data • Hepatocellular Cancer

Targeting A3 adenosine receptor signaling to enhance analgesia in nonresponders to spinal cord stimulation in male nerve-injured rats. (PubMed, Pain) - "The dose-response relationship of 2-Cl-IB-MECA (a highly selective A3AR agonist) to inhibit mechanical hypersensitivity in male SNI-t rats after intraperitoneal injection was first established by measuring the paw withdrawal thresholds...Notably, the pain reduction from repeated SCS was accompanied by a shift toward an anti-inflammatory microglial phenotype. These findings suggest that persistent microglial activation in male SNI-t rats may contribute to SCS nonresponsiveness, and that engaging A3AR signaling represents a promising strategy to convert nonresponders into SCS responders in NP conditions."

Journal • Preclinical • Immunology • Neuralgia • Pain

CF102. Extreme Hyperthermia...but Is It Malignant Hyperthermia? MH Experts Opine (1 CME) (ASA 2026) - "This clinical forum is comprised of four physician consultants for the malignant hyperthermia (MH) hotline of MHAUS. We hope to increase learners' confidence in the care of patients during MH or MH-like events. SessionLearningObjective1: Identify the signs and symptoms of an MH crisis.SessionLearningObjective2: Differentiate between true MH and other mimicking disease processes that cause severe hyperthermia.SessionLearningObjective3: Identify the role of dantrolene in differential diagnosis of MH and its potential use in other causes of severe hyperthermia."

Can-Fite BioPharma…announced new preclinical findings demonstrating that namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer (GlobeNewswire) - "In pre-clinical studies the combination of namodenoson and gemcitabine increased the level of a protein, cleaved caspase-3, a central mediator of cell death (apoptosis). These findings indicate that namodenoson weakens the survival mechanisms of pancreatic cancer cells, thereby increasing their susceptibility to chemotherapy and enabling a stronger tumor cell-death response. The new findings directly support the scientific rationale underlying Can-Fite’s planned randomized Phase IIb study in advanced pancreatic adenocarcinoma. The proposed study will evaluate namodenoson in combination with gemcitabine and additional standard-of-care therapy..."

New P2b trial • Preclinical • Pancreatic Adenocarcinoma

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates (The Manila Times) - "Namodenoson, Can-Fite’s orally administered A3 adenosine receptor (A3AR) agonist, is currently being evaluated in a pivotal Phase III study for the treatment of patients with advanced liver cancer, hepatocellular carcinoma (HCC) and underlying Child-Pugh B7 liver cirrhosis. The Phase III study is being conducted under regulatory guidance from both the FDA and EMA and is designed to support potential marketing authorization applications in the United States and Europe, if the study meets its predefined efficacy and safety endpoints."

Trial status • Hepatocellular Cancer

Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology (GlobeNewswire) - "Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months."

P2a data • Pancreatic Ductal Adenocarcinoma

Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer (GlobeNewswire) - "...Australian Patent Office has allowed Patent Application No. 2021290439...The patent complements Can-Fite's rapidly advancing oncology pipeline."

Patent • Pancreatic Cancer

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease (The Manila Times) - "Among the eight evaluable third-line patients: Median overall survival exceeded 5 months; 62.5% of patients survived five months or longer; 37.5% survived seven months or longer; Two patients remain alive at the data cutoff, including one patient continuing treatment and another followed for almost nine months; Durable disease control was observed, including progression-free survival extending beyond seven months....Based on these findings and discussions with the study's principal investigator, Can-Fite plans to advance Namodenoson into a Phase 2b combination study with chemotherapy."

New P2b trial • P2a data • Pancreatic Ductal Adenocarcinoma

A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical Translation. (PubMed, Biomolecules) - "Importantly, these mechanistic insights have been translated into clinical programs, with piclidenoson and namodenoson demonstrating favorable safety profiles and disease-modifying activity in inflammatory, fibrotic, and oncologic indications. This review integrates molecular, cellular, and translational evidence to highlight A3AR activation as a unifying therapeutic principle for diseases driven by inflammation, oxidative stress, hypoxia, and dysregulated cell survival, positioning selective A3AR agonists as first-in-class agents targeting the A3AR, with broad clinical applicability across multiple disease domains."

Journal • Review • Cardiovascular • CNS Disorders • Dermatology • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Ischemic stroke • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Oncology • Ophthalmology • Osteoarthritis • Pain • Pancreatic Cancer • Psoriasis • Rheumatoid Arthritis • Rheumatology • Solid Tumor • CTNNB1

Can-Fite BioPharma Ltd. reports that the Japan Patent Office has allowed a patent covering the use of A3 adenosine receptor agonists, including its lead drug Namodenoson, for fat loss, obesity and related metabolic disorders. (StockTitan.net) - "Namodenoson’s value and future partnering opportunities in an obesity therapeutics market forecast to exceed $60 billion by 2030."

Patent • Sales projection • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity

Endothelial SHMT2 Drives Pulmonary Vascular Remodeling Through Noncanonical Pathway in Pulmonary Hypertension. (PubMed, Circulation) - "Through virtual screening, Namodenoson was identified as a small-molecule inhibitor targeting the SHMT2-RhoB pathway...This study highlights endothelial SHMT2 as an important contributor to PH pathogenesis and reveals a noncanonical SHMT2-RhoB pathway that promotes endothelial dysfunction. Targeting this pathway may represent a potential therapeutic strategy for PH."

Journal • Cardiovascular • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Targeted Protein Degradation • SHMT2

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism (GlobeNewswire) - "Recent presentations and publications emerging from the 2026 American Society of Clinical Oncology (ASCO) meeting have reinforced the importance of targeting RAS-driven malignancies, particularly pancreatic ductal adenocarcinoma (PDAC), where KRAS mutations and downstream RAS activation are central drivers of tumor growth and therapeutic resistance....The Company also reported encouraging clinical observations from its Phase 2a study of namodenoson as a monotherapy in pancreatic cancer. Enrollment has been completed and several patients have demonstrated prolonged disease control, including one patient who has remained on therapy and follow-up for approximately 16 months."

P2a data • Pancreatic Ductal Adenocarcinoma

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy (The Manila Times) - "The upcoming Phase 2b study is expected to evaluate Namodenoson in combination with immunotherapy in order to further assess clinical benefit, including progression-free survival, overall survival, disease stabilization, and additional efficacy endpoints...The Company further announced that details of the planned Phase 2b study design are expected to be discussed during the upcoming BIO International Convention in San Diego."

New P2b trial • Pancreatic Cancer

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months (GlobeNewswire) - "Key findings include: Stable disease observed in >30% of evaluable patients; Prolonged treatment duration includes one patient extending beyond 16 months. 35% of patients remain on therapy and follow up; Favorable safety and tolerability profile consistent with prior reports."

P2a data • Pancreatic Ductal Adenocarcinoma

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance (GlobeNewswire) - "The allowed patent covers the use of A3 adenosine receptor (A3AR) agonists, including the Company’s lead drug candidate Namodenoson, for inducing fat loss and treating obesity and related metabolic disorders. This allowance represents a key addition to Can-Fite’s expanding global intellectual property portfolio around Namodenoson’s anti-obesity activity and follows similar patent advancements in other major jurisdictions including the US, Canada and Australia, strengthening the Company’s worldwide protection strategy."

Patent • Metabolic Disorders • Obesity

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study (Yahoo Finance) - "The study met its primary endpoint, which was safety, demonstrating that namodenoson was very well tolerated in this heavily pretreated patient population. No new safety signals were identified, and the safety profile was consistent with the known clinical experience of namodenoson in other oncological diseases...Secondary endpoints included overall survival (OS) and progression-free survival (PFS). Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off. As follow-up continues, survival outcomes are expected to further mature and will be announced during upcoming scientific meetings."

P2a data • Pancreatic Ductal Adenocarcinoma

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson (GlobeNewswire) - "The study evaluated the effects of namodenoson in adipocytes (3T3-L1 fat cells) in vitro and in a murine high-fat diet model of obesity....The publication reports that namodenoson significantly inhibited adipocyte proliferation and lipid droplet accumulation in a dose-dependent manner. In the high-fat diet model, daily oral administration of namodenoson for four weeks resulted in a statistically significant reduction in weight gain compared to placebo-treated controls."

Preclinical • Obesity

The anti-obesity effect of namodenoson, an A3 adenosine receptor agonist. (PubMed, Int J Obes (Lond)) - "The same experiment on mice fed a lean diet demonstrated no namodenoson effect (mean weight: 33.5 ± 3.9 vs 33.0 ± 0.6 g, respectively). In conclusion, our findings support continued investigation of namodenoson as a weight-loss drug candidate."

Journal • Genetic Disorders • Hepatocellular Cancer • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Oncology • Solid Tumor • CTNNB1 • PPARG

Can-Fite BioPharma…announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled 'An A3 adenosine receptor ligand for use for achieving a fat loss effect' (GlobeNewswire) - "The patent covers the use of Namodenoson, Can-Fite’s orally bioavailable A3 adenosine receptor (A3AR) agonist, for reducing fat mass and body weight, providing intellectual property protection in Canada for its development as an anti-obesity therapy....The anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental animal model of obesity, induced by high fat diet."

Patent • Obesity

Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson (GlobeNewswire) - "The patient received Namodenoson treatment under a compassionate use framework while suffering from liver disease and complications consistent with decompensated cirrhosis. Throughout the treatment period, Namodenoson contributed to clinical stabilization, allowing the patient to remain a suitable candidate for liver transplantation until a compatible donor organ became available, ultimately resulting in a successful, life-saving liver transplantation. While this is a single case, the outcome suggests a potential supportive role for Namodenoson in patients with severe liver dysfunction awaiting transplantation."

Clinical • Liver Cirrhosis • Transplantation

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson (GlobeNewswire) - "The Phase 2a study is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy....Top-Line Efficacy Data Expected in Q3 2026."

Enrollment closed • P2a data • Pancreatic Adenocarcinoma

Can-Fite Provides Update on Clinical and Financial Status (GlobeNewswire) - "An interim analysis from the Phase III study is expected to be in approximately Q4 2026. Subject to positive interim results, the Company may be eligible to seek conditional regulatory approval from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)....In addition, Namodenoson is being evaluated in a Phase IIa clinical study in patients with pancreatic cancer who have failed first-line treatment. Patient enrollment in this study is nearing completion, and the Company expects to report data during the second quarter of 2026."

P2a data • P3 data • Hepatocellular Cancer • Pancreatic Adenocarcinoma • Pancreatic Cancer

Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference (GlobeNewswire) - "Mr. Farbstein will present the latest developments in Can-Fite’s advanced stage drug development pipeline including the following trials: Phase III liver cancer; Phase IIa pancreatic cancer; Phase III psoriasis; Phase IIb MASH..."

Trial status • Liver Cancer • Metabolic Dysfunction-Associated Steatohepatitis • Pancreatic Cancer • Psoriasis